PE20240372A1 - Anticuerpos y composiciones anti-nkg2a - Google Patents

Anticuerpos y composiciones anti-nkg2a

Info

Publication number
PE20240372A1
PE20240372A1 PE2023003150A PE2023003150A PE20240372A1 PE 20240372 A1 PE20240372 A1 PE 20240372A1 PE 2023003150 A PE2023003150 A PE 2023003150A PE 2023003150 A PE2023003150 A PE 2023003150A PE 20240372 A1 PE20240372 A1 PE 20240372A1
Authority
PE
Peru
Prior art keywords
compositions
nkg2a antibodies
nkg2a
antibodies
cancer
Prior art date
Application number
PE2023003150A
Other languages
English (en)
Inventor
Randi Westh Hansen
Franziska Katharina Uhlenbrock
Nikolaj Dietrich
Anne Worsaae
Michael Monrad Grandal
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Servier Lab filed Critical Servier Lab
Publication of PE20240372A1 publication Critical patent/PE20240372A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Esta invencion se refiere a anticuerpos anti-NKG2A y a metodos para usarlos para aumentar la inmunidad en un paciente que lo necesita y en el tratamiento del cancer
PE2023003150A 2021-06-01 2022-05-31 Anticuerpos y composiciones anti-nkg2a PE20240372A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163195470P 2021-06-01 2021-06-01
PCT/EP2022/064703 WO2022253805A1 (en) 2021-06-01 2022-05-31 Anti-nkg2a antibodies and compositions

Publications (1)

Publication Number Publication Date
PE20240372A1 true PE20240372A1 (es) 2024-03-05

Family

ID=82117230

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2023003150A PE20240372A1 (es) 2021-06-01 2022-05-31 Anticuerpos y composiciones anti-nkg2a

Country Status (15)

Country Link
US (1) US12012450B2 (es)
EP (1) EP4347651A1 (es)
JP (1) JP2024520577A (es)
KR (1) KR20240016991A (es)
CN (1) CN117460748A (es)
AR (1) AR126001A1 (es)
AU (1) AU2022286617A1 (es)
BR (1) BR112023024772A2 (es)
CA (1) CA3222040A1 (es)
CO (1) CO2023015982A2 (es)
IL (1) IL308695A (es)
MX (1) MX2023014320A (es)
PE (1) PE20240372A1 (es)
TW (1) TW202313683A (es)
WO (1) WO2022253805A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024140820A1 (zh) * 2022-12-28 2024-07-04 浙江博锐生物制药有限公司 抗nkg2a抗体及其用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1105427A2 (en) 1998-08-17 2001-06-13 Abgenix, Inc. Generation of modified molecules with increased serum half-lives
DK2374818T3 (da) * 2006-06-02 2013-01-21 Regeneron Pharma Højaffinitetsantistoffer mod human IL-6-receptor
WO2009092805A1 (en) 2008-01-24 2009-07-30 Novo Nordisk A/S Humanized anti-human nkg2a monoclonal antibody
SG11201701387SA (en) 2014-09-16 2017-03-30 Innate Pharma Treatment regimens using anti-nkg2a antibodies
KR102598068B1 (ko) * 2014-10-23 2023-11-06 이나뜨 파르마 에스.에이. 항-ｎｋｇ2ａ 제제를 이용하는 암 치료
WO2017046774A2 (en) * 2015-09-16 2017-03-23 Prothena Biosciences Limited Use of anti-mcam antibodies for treatment or prophylaxis of giant cell arteritis, polymyalgia rheumatica or takayasu's arteritis
CA3020647A1 (en) 2016-04-12 2017-10-19 Symphogen A/S Anti-tim-3 antibodies and compositions
CN111153995B (zh) * 2018-11-07 2020-12-25 上海怀越生物科技有限公司 Nkg2a抗体及其制备方法和应用
BR112021009111A2 (pt) * 2018-11-16 2021-08-24 Bristol-Myers Squibb Company Anticorpos anti-nkg2a e usos dos mesmos

Also Published As

Publication number Publication date
IL308695A (en) 2024-01-01
AU2022286617A1 (en) 2023-12-21
BR112023024772A2 (pt) 2024-02-15
CN117460748A (zh) 2024-01-26
MX2023014320A (es) 2023-12-13
TW202313683A (zh) 2023-04-01
CA3222040A1 (en) 2022-12-08
JP2024520577A (ja) 2024-05-24
WO2022253805A1 (en) 2022-12-08
KR20240016991A (ko) 2024-02-06
CO2023015982A2 (es) 2024-01-15
US12012450B2 (en) 2024-06-18
EP4347651A1 (en) 2024-04-10
US20220389100A1 (en) 2022-12-08
AR126001A1 (es) 2023-08-30

Similar Documents

Publication Publication Date Title
PE20210488A1 (es) Anticuerpos especificos para gucy2c y sus usos
CO2019004003A2 (es) Composiciones y anticuerpos anti-lag-3
CO2021001912A2 (es) Composiciones anti-cd112r y métodos
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CL2019001874A1 (es) Inhibidores de tgfß1 isoforma-específicos contexto-permisivos y uso de los mismos.
CL2019000277A1 (es) Tratamiento conjunto contra el cáncer.
CL2019002850A1 (es) Terapias combinadas dirigidas a pd-1, tim-3, y lag-3.
PE20180268A1 (es) Composiciones que comprenden cepas bacterianas
PE20210167A1 (es) Proteinas de union multiespecificas y mejoras con estas
AR113881A1 (es) Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia
CL2016000538A1 (es) Compuesto que comprende la proteína globo h y klh, composiciones de una vacuna de hidratos de carbono para la inducción de respuestas inmunes y usos de los mismos
CL2017000317A1 (es) Terapia adjuntiva con 25-hidroxi vitamina d
CO2023015982A2 (es) Anticuerpos anti-nkg2a y composiciones
CU20160133A7 (es) Anticuerpos anti-mcam y métodos de uso asociados
CL2019002368A1 (es) Composiciones y métodos para el tratamiento de cáncer.
CO2022002622A2 (es) Anticuerpos anti-cd73 y composiciones
CL2022002833A1 (es) Anticuerpos anti-flt3 y composiciones
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
CO2019007686A2 (es) Anticuerpos anti-properdina monovalentes y fragmentos de anticuerpo
CO2019007205A2 (es) Usos terapéuticos de un polvo de insectos
CL2018002810A1 (es) Anticuerpos anti-factor bb del complemento y usos de estos referencia cruzada.
CL2020002624A1 (es) Formulaciones de inmunoconjugado anti-cd79b estables.
CO2020005919A2 (es) Compuestos y composiciones farmaceuticas de los mismos para usarse en el tratamiento de enfermedades fibroticas
CL2023000892A1 (es) Composiciones terapéuticas y métodos para el tratamiento de la hepatitis b (divisional).
CL2021000924A1 (es) Uso de reboxetina para el tratamiento de narcolepsia